| Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real–Life” Patients With Atrial Fibrillation P Šinigoj, RE Malmström, N Vene, Y Rönquist‐Nii, M Božič‐Mijovski, ... Basic & clinical pharmacology & toxicology 117 (5), 323-329, 2015 | 53 | 2015 |
| Ticagrelor versus clopidogrel in comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention and hypothermia: a randomized study K Steblovnik, A Blinc, MB Mijovski, M Fister, U Mikuz, M Noc Circulation 134 (25), 2128-2130, 2016 | 46 | 2016 |
| Intra-and inter-individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation M Miklič, A Mavri, N Vene, L Söderblom, M Božič-Mijovski, A Pohanka, ... European journal of clinical pharmacology, 1-7, 2019 | 42 | 2019 |
| Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations M Božič-Mijovski, RE Malmström, P Malovrh, JP Antovic, N Vene, ... Annals of clinical biochemistry 53 (4), 446-451, 2016 | 38 | 2016 |
| Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. K Steblovnik, A Blinc, M Bozic-Mijovski, I Kranjec, E Melkic, M Noc EuroIntervention: journal of EuroPCR in collaboration with the Working Group …, 2015 | 32 | 2015 |
| Hyperhomocysteinemia and thrombophilia M Božič-Mijovski Clinical chemistry and laboratory medicine 48, S89-S95, 2010 | 23 | 2010 |
| The effect of pre-analytical variables on light transmittance aggregometry in citrated platelet-rich plasma from healthy subjects M Stegnar, A Kneževič, M Božič-Mijovski Clinical chemistry and laboratory medicine 48 (10), 1463-1465, 2010 | 19 | 2010 |
| Variation in platelet function testing has a major influence on detection of aspirin resistance in healthy subjects M Božič-Mijovski, M Rakuša, M Stegnar Pathophysiology of haemostasis and thrombosis 36 (2), 84-90, 2007 | 13 | 2007 |
| Increased coagulation and decreased fibrinolysis as measured with overall hemostatic potential are dependent on BMI and not associated with PCOS M Rakusa, M Jensterle, M Božič-Mijovski, A Janez Metabolic syndrome and related disorders 15 (4), 194-198, 2017 | 11 | 2017 |
| Nurr1 haplotypes are associated with femoropopliteal restenosis/re-occlusion after percutaneous transluminal angioplasty M Božič-Mijovski, M Bedenčič, M Stegnar, V Salapura, MK Ježovnik, ... European Journal of Vascular and Endovascular Surgery 43 (3), 337-338, 2012 | 8 | 2012 |
| Laboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome P Žigon, M Božič-Mijovski, MF Bertoncelj, A Ambrožič, M Tomšič, ... Thrombosis, Atherosclerosis and Atherothrombosis: New Insights and …, 2015 | 4 | 2015 |
| Is Restenosis/Reocclusion after Femoropopliteal Percutaneous Transluminal Angioplasty (PTA) the Consequence of Reduced Blood Flow, Inflammation, and/or Hemostasis Disturbances? M Božič-Mijovski, V Boc, V Salapura, A Blinc, M Stegnar Thrombosis, Atherosclerosis and Atherothrombosis: New Insights and …, 2015 | 4 | 2015 |
| Ex vivo neutralization of unfractionated heparin for assessing overall haemostatic potential in patient plasma M Božič-Mijovski, M Vučnik, V Boc, A Blinc, M Stegnar Thrombosis research 135 (5), 1042-1044, 2015 | 4 | 2015 |
| Rotational thromboelastometry in ex vivo samples from routine clinical practice patients receiving dabigatran. M Božič-Mijovski, N Vene, N Snoj, P Gradišek, A Mavri Clinica chimica acta; international journal of clinical chemistry 466, 20, 2017 | 3 | 2017 |
| Increased Plasma Cathepsin S at the Time of Percutaneous Transluminal Angioplasty is Associated with 6-Months’ Restenosis of the Femoropopliteal Artery MB Mijovski, V Boc, UP Fonovic, J Marc, A Blinc, J Kos, D Cerne Journal of medical biochemistry 37 (1), 54-61, 2018 | 2 | 2018 |
| C0180: Anti-Xa Assay for Measurement of Plasma Rivaroxaban is Not Affected by the Addition of Exogenous Antithrombin M Bozic-Mijovski, P Malovrh Thrombosis Research 133, S85-S86, 2014 | 2 | 2014 |
| Association of haemostasis activation markers with thrombophilia and venous thromboembolism T Vižintin-Cuderman, M Božič-Mijovski, A Antović, P Peternel, M Kozak, ... Thrombophilia. InTech, Rijeka, Croatia, 23-38, 2011 | 2 | 2011 |
| Anticoagulant Drugs M Božič-Mijovski BoD–Books on Demand, 2018 | 1 | 2018 |
| Measuring hypercoagulability as a risk factor for cardiovascular diseases M Božič-Mijovski Handbook of nutrition and diet in leukemia and blood disease therapy, 31-48, 2016 | 1 | 2016 |
| P1640 Classical risk factors are more important for prognosis of patients with peripheral arterial disease than selected genetic polymorphisms A Blinc, V Boc, M Pohar Perme, M Bozic Mijovski, PID PAB investigators European Heart Journal 39 (suppl_1), ehy565. P1640, 2018 | | 2018 |
